Cyclophosphamide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CYCLOPHOSPHAMIDE |
|---|---|
| Type | Drug |
| Aliases | CytoxanEndoxanProcytoxЦиклофосфамід |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-AITL DIS-ALCL DIS-ATLL DIS-B-ALL DIS-BREAST DIS-BURKITT DIS-DLBCL-NOS DIS-EATL DIS-FL DIS-HGBL-DH DIS-HSTCL DIS-MCL DIS-MELANOMA DIS-MM DIS-NLPBL DIS-PMBCL DIS-PTCL-NOS DIS-PTLD DIS-T-ALL DIS-WM |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | alkylating_agent — nitrogen mustard (oxazaphosphorine) |
|---|---|
| Mechanism | Prodrug activated by hepatic CYP2B6/CYP3A4 to phosphoramide mustard, which crosslinks DNA strands and induces apoptosis. Active in both proliferating and resting cells; broadly used in lymphoid neoplasms. |
| Typical dosing | 750 mg/m² IV day 1 of 21-day cycle (R-CHOP); 600-1500 mg/m² depending on regimen |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Myelosuppression with infection risk
- Hemorrhagic cystitis (mitigated by mesna for high-dose)
- Cardiotoxicity at very high doses
- Secondary malignancies (long-term exposure)
Notes
Standard R-CHOP component. Premedication: 5-HT3 antagonist + dexamethasone. Mesna NOT routinely needed at R-CHOP doses (750 mg/m²) but mandatory for high-dose conditioning (>1500 mg/m²).
Used By
Regimens
REG-CAR-T-AXICEL- Axicabtagene ciloleucel (axi-cel) CAR-T — single infusion after lymphodepletionREG-CAR-T-AXICEL-FL- Axicabtagene ciloleucel (axi-cel) CAR-T for r/r FL — single infusion after lymphodepletio...REG-CAR-T-AXICEL-HGBL- Axicabtagene ciloleucel (axi-cel CAR-T) for relapsed/refractory HGBL-DHREG-CAR-T-BREXUCEL-MCL- Brexucabtagene autoleucel (brexu-cel) CAR-T for r/r MCL — single infusion after lymphodep...REG-CHOEP- CHOEP (cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone), 6 cyclesREG-CHOEP-ALLOSCT-CONSOLIDATION- CHOEP × 6 + allogeneic SCT consolidation in CR1 (fit transplant-eligible PTCL NOS)REG-CHP-BV- Brentuximab vedotin + CHP (CHP-Bv), 6 cycles (CD30+ T-cell lymphomas)REG-CILTACEL-LYMPHODEPLETION-FLU-CY- Lymphodepleting fludarabine + cyclophosphamide conditioning before ciltacabtagene autoleu...REG-CILTACEL-MM-2L- Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T for lenalidomide-refractory R/R multiple...REG-CILTACEL-MM-3L- Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T for R/R multiple myeloma after ≥3 prior...REG-CODOX-M-IVAC- CODOX-M / IVAC alternating × 4 (Magrath protocol)REG-DA-EPOCH-R- Dose-Adjusted EPOCH + Rituximab (DA-EPOCH-R), 6 cyclesREG-DRC-WM- Dexamethasone + Rituximab + Cyclophosphamide (DRC) × 6 cyclesREG-HYPER-CVAD-R- Hyper-CVAD + Rituximab (CD20+) — alternating courses A/B, 8 cycles totalREG-IDECEL-LYMPHODEPLETION-FLU-CY- Lymphodepleting fludarabine + cyclophosphamide conditioning before idecabtagene vicleucel...REG-IDECEL-MM-3L- Idecabtagene vicleucel (ide-cel) BCMA CAR-T for triple-class-exposed R/R multiple myeloma...REG-LIFILEUCEL-TIL-MELANOMA- Lifileucel TIL therapy (Amtagvi, melanoma 3L+)REG-MCL-INTENSIVE-RDHAP-AUTOSCT- Intensive 1L MCL: alternating R-CHOP / R-DHAP × 6 cycles + autoSCT consolidation + R main...REG-PEMBRO-CHEMO-TNBC-NEOADJUVANT- Pembrolizumab + chemo (TNBC neoadjuvant)REG-POLA-R-CHP- Polatuzumab vedotin + Rituximab + CHP (Pola-R-CHP), 6 cycles + 2× rituximabREG-R-CHOP- Rituximab + CHOP (R-CHOP), 6 cyclesREG-TISAGENLECLEUCEL-B-ALL- Tisagenlecleucel CD19 CAR-T for R/R B-ALL ≤25 yearsREGIMEN-LISOCEL-DLBCL-2L- Lisocabtagene maraleucel (liso-cel) CAR-T 2L for primary-refractory or early-relapse LBCL...REGIMEN-LISOCEL-DLBCL-3L- Lisocabtagene maraleucel (liso-cel) CAR-T for r/r LBCL ≥3L (TRANSCEND NHL 001)